Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis

Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis

Abstract Introduction Lebrikizumab is a novel monoclonal antibody that selectively binds to interleukin (IL)-13 with high affinity and a slow dissociation rate. Methods We assayed serum from select patients enrolled in ADvocate1 and ADvocate2 to determine the impact of lebrikizumab on circulating bi...

Full description

Saved in:
Bibliographic Details
Main Authors: Emma Guttman-Yassky, Zhe Sun, Laura Rebeca Mena, Nathan Hahn, Brian J. Nickoloff, Christoph Preuss, Kimberly Siu, Chitra R. Natalie, Gaia Gallo, Eric Wolf, Kilian Eyerich, Mònica Aparici, Robert J. Benschop, Angela Okragly
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-07-01
Series:Dermatology and Therapy
Subjects:
Atopic dermatitis
Biomarkers
Interleukin-13
Lebrikizumab
Online Access:https://doi.org/10.1007/s13555-025-01481-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-025-01481-4

Similar Items